hydrochlorothiazide has been researched along with Disease Exacerbation in 21 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial showed that initial antihypertensive therapy with benazepril plus amlodipine was superior to benazepril plus hydrochlorothiazide in reducing cardiovascular morbidity and mortality." | 5.14 | Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. ( Bakris, GL; Chiang, YT; Dahlöf, B; Jamerson, K; Kelly, RY; Pitt, B; Sarafidis, PA; Shi, V; Staikos-Byrne, L; Velazquez, EJ; Weber, MA; Weir, MR, 2010) |
| "The Plaque Hypertension Lipid-Lowering Italian Study (PHYLLIS) tested whether (1) the angiotensin-converting enzyme (ACE) inhibitor fosinopril (20 mg per day) was more effective on carotid atherosclerosis progression than the diuretic hydrochlorothiazide (25 mg per day), (2) pravastatin (40 mg per day) was more effective than placebo when added to either hydrochlorothiazide or fosinopril, and (3) there were additive effects of ACE inhibitor and lipid-lowering therapies." | 5.11 | Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind trial. ( Baggio, G; Bond, MG; Crepaldi, G; Gallus, G; Magni, A; Mancia, G; Rubba, P; Sampieri, L; Sperti, G; Veglia, F; Ventura, A; Zanchetti, A, 2004) |
| "Hypertension treatment with doxazosin or HCTZ resulted in a comparable change in arterial IMT after three years, in spite of differences in effect on plasma lipids." | 5.10 | Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands. ( Birkenhägeri, JC; de Groot, E; de Heide, LH; de Ridder, MA; Hoogerbrugge, N; Jansen, H; Stijnen, T, 2002) |
| " The study was designed as a side arm of INSIGHT (International Nifedipine Study: Intervention as Goal for Hypertension Therapy), aimed to show the efficacy of nifedipine once daily versus co-amilozide (hydrochlorothiazide 25 mg, amiloride 2." | 5.09 | Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. ( Motro, M; Shemesh, J, 2001) |
| "This study, ancillary to the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT), involved nifedipine 30 mg or co-amilozide (hydrochlorothiazide 25 mg and amiloride 2." | 5.09 | Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. ( Gariépy, J; Levenson, J; Moyse, D; Simon, A, 2001) |
| "The effect of hydrochlorothiazide (HCTZ) on clinical and radiologic progression of nephrocalcinosis was evaluated in 11 children with XLH." | 5.09 | Thiazide diuretics arrest the progression of nephrocalcinosis in children with X-linked hypophosphatemia. ( Baum, M; Seikaly, MG, 2001) |
| " After 4 weeks of DOCA-salt hypertension, rats were either killed (n = 6), or treated with a non-hypotensive dose of spironolactone (n = 7) or triple therapy (hydrochlorothiazide, reserpine and hydralazine, n = 8) to normalize blood pressure or with vehicle (n = 19) for two further weeks." | 3.74 | Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension. ( Cordasic, N; Hartner, A; Hilgers, KF; Klanke, B; Schmieder, RE; Veelken, R, 2008) |
| " The aim of this study was to compare the effects of an equivalent reduction in blood pressure produced by the angiotensin-converting enzyme (ACE) inhibitor spirapril (SPI) and an antihypertensive triple drug combination of hydralazine, reserpine and hydrochlorothiazide (HRH) on kidney function, proteinuria and renal structure in hypertensive diabetic rats." | 3.70 | Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats. ( Armini, L; Bardelli, M; Calci, M; Campanacci, L; Candido, R; Carretta, R; Fabris, B; Fazio, M; Fischetti, F, 1999) |
| " After a 4-week wash-out period, 209 patients were randomized to either CC 8 mg or AML 5 mg once daily for a minimum of 1 month, after which, if BP was not normalized, the dosage was doubled, followed by the addition of hydrochlorothiazide 12." | 2.74 | Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study. ( Asmar, R; Baguet, JP; Mallion, JM; Nisse-Durgeat, S; Valensi, P, 2009) |
| "In 562 patients with ADPKD (61% female, eGFR 63±28 ml/min per 1." | 1.91 | Prostaglandin E2, Osmoregulation, and Disease Progression in Autosomal Dominant Polycystic Kidney Disease. ( Fenton, RA; Gansevoort, RT; Geurts, F; Hoorn, EJ; Kramers, BJ; Meijer, E; Salih, M; Xue, L; Zietse, R, 2023) |
| " Here, we evaluated whether chronic administration of an NO donor, molsidomine, controlled systemic blood pressure and renal disease progression and prolonged survival in rats with renal mass reduction (RMR)." | 1.30 | Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. ( Benedetti, G; Benigni, A; Bruzzi, I; Corna, D; Noris, M; Remuzzi, G; Todeschini, M; Zoja, C, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (14.29) | 18.2507 |
| 2000's | 11 (52.38) | 29.6817 |
| 2010's | 6 (28.57) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Geurts, F | 1 |
| Xue, L | 1 |
| Kramers, BJ | 1 |
| Zietse, R | 1 |
| Gansevoort, RT | 1 |
| Fenton, RA | 1 |
| Meijer, E | 1 |
| Salih, M | 1 |
| Hoorn, EJ | 1 |
| Matsushima, T | 1 |
| Nakajima, H | 1 |
| Ohko, K | 1 |
| Nakajima, K | 1 |
| Sano, S | 1 |
| Klanke, B | 1 |
| Cordasic, N | 1 |
| Hartner, A | 1 |
| Schmieder, RE | 1 |
| Veelken, R | 1 |
| Hilgers, KF | 1 |
| Perico, N | 1 |
| Cattaneo, D | 1 |
| Remuzzi, G | 2 |
| Baguet, JP | 1 |
| Asmar, R | 1 |
| Valensi, P | 1 |
| Nisse-Durgeat, S | 1 |
| Mallion, JM | 1 |
| Heerspink, HL | 1 |
| de Zeeuw, D | 1 |
| Bakris, GL | 1 |
| Sarafidis, PA | 1 |
| Weir, MR | 1 |
| Dahlöf, B | 1 |
| Pitt, B | 1 |
| Jamerson, K | 1 |
| Velazquez, EJ | 1 |
| Staikos-Byrne, L | 1 |
| Kelly, RY | 1 |
| Shi, V | 1 |
| Chiang, YT | 1 |
| Weber, MA | 1 |
| Satoh, F | 1 |
| Okado, T | 1 |
| Iwamoto, M | 1 |
| Akita, W | 1 |
| Wakabayashi, M | 1 |
| Ohta, A | 1 |
| Sohara, E | 1 |
| Noda, Y | 1 |
| Rai, T | 1 |
| Uchida, S | 1 |
| Sasaki, S | 1 |
| Basile, J | 1 |
| Babazadeh, S | 1 |
| Lillestol, M | 1 |
| Botha, J | 1 |
| Yurkovic, C | 1 |
| Weitzman, R | 1 |
| Lee, SC | 1 |
| Dalia, SM | 1 |
| Hoogerbrugge, N | 1 |
| de Groot, E | 1 |
| de Heide, LH | 1 |
| de Ridder, MA | 1 |
| Birkenhägeri, JC | 1 |
| Stijnen, T | 1 |
| Jansen, H | 1 |
| Zanchetti, A | 1 |
| Crepaldi, G | 1 |
| Bond, MG | 2 |
| Gallus, G | 1 |
| Veglia, F | 1 |
| Mancia, G | 1 |
| Ventura, A | 1 |
| Baggio, G | 1 |
| Sampieri, L | 1 |
| Rubba, P | 1 |
| Sperti, G | 1 |
| Magni, A | 1 |
| Kamgar, M | 1 |
| Nobakhthaghighi, N | 1 |
| Shamshirsaz, AA | 1 |
| Estacio, RO | 1 |
| McFann, KK | 1 |
| Schrier, RW | 1 |
| Tylicki, L | 1 |
| Rutkowski, P | 1 |
| Renke, M | 1 |
| Larczyński, W | 1 |
| Aleksandrowicz, E | 1 |
| Lysiak-Szydlowska, W | 1 |
| Rutkowski, B | 1 |
| Borhani, NO | 1 |
| Mercuri, M | 1 |
| Borhani, PA | 1 |
| Buckalew, VM | 1 |
| Canossa-Terris, M | 1 |
| Carr, AA | 1 |
| Kappagoda, T | 1 |
| Rocco, MV | 1 |
| Schnaper, HW | 1 |
| Sowers, JR | 1 |
| Benigni, A | 1 |
| Zoja, C | 1 |
| Noris, M | 1 |
| Corna, D | 1 |
| Benedetti, G | 1 |
| Bruzzi, I | 1 |
| Todeschini, M | 1 |
| Fabris, B | 1 |
| Candido, R | 1 |
| Armini, L | 1 |
| Fischetti, F | 1 |
| Calci, M | 1 |
| Bardelli, M | 1 |
| Fazio, M | 1 |
| Campanacci, L | 1 |
| Carretta, R | 1 |
| Motro, M | 1 |
| Shemesh, J | 1 |
| Simon, A | 1 |
| Gariépy, J | 1 |
| Moyse, D | 1 |
| Levenson, J | 1 |
| Burgess, HK | 1 |
| Jayawardene, SA | 1 |
| Velasco, N | 1 |
| Seikaly, MG | 1 |
| Baum, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension[NCT00170950] | Phase 3 | 11,506 participants (Actual) | Interventional | 2003-10-31 | Terminated (stopped due to The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CV mortality was defined as death due to sudden cardiac death, fatal MI, fatal stroke, coronary intervention, congestive heart failure (CHF), or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV mortality event, MI (non-fatal), or stroke (non-fatal) (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
| Intervention | Percentage of Patients with an Event (Number) |
|---|---|
| Benazepril/Amlodipine | 5.0 |
| Benazepril/Hydrochlorothiazide | 6.3 |
Cardiovascular morbidity was defined as including any of the following events: non-fatal MI, non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure (PCI or CABG). (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])]
| Intervention | Percentage of Patients with an Event (Number) |
|---|---|
| Benazepril/Amlodipine | 8.6 |
| Benazepril/Hydrochlorothiazide | 10.3 |
CV morbidity was defined as non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure. CV mortality was defined as death due to MI, stroke, coronary intervention, congestive heart failure (CHF), sudden cardiac death, or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity or mortality event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
| Intervention | Percentage of Patients with an event (Number) |
|---|---|
| Benazepril/Amlodipine | 9.6 |
| Benazepril/Hydrochlorothiazide | 11.8 |
10 trials available for hydrochlorothiazide and Disease Exacerbation
| Article | Year |
|---|---|
Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2009 |
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Be | 2010 |
Comparison of aliskiren/hydrochlorothiazide combination therapy with hydrochlorothiazide monotherapy in older patients with stage 2 systolic hypertension: results of the ACTION study.
Topics: Age Factors; Aged; Amides; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Body Mass | 2011 |
Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands.
Topics: Aged; Antihypertensive Agents; Arteriosclerosis; Carotid Arteries; Disease Progression; Diuretics; D | 2002 |
Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antihypertensive Agents; C | 2004 |
Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Topics: Acetylglucosaminidase; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2008 |
Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial.
Topics: Aged; Antihypertensive Agents; Arteriosclerosis; Carotid Arteries; Diastole; Disease Progression; Di | 1996 |
Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics.
Topics: Aged; Amiloride; Calcinosis; Calcium Channel Blockers; Cardiomyopathies; Coronary Artery Disease; Di | 2001 |
Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes.
Topics: Aged; Aged, 80 and over; Amiloride; Antihypertensive Agents; Atenolol; Blood Pressure; Carotid Arter | 2001 |
Thiazide diuretics arrest the progression of nephrocalcinosis in children with X-linked hypophosphatemia.
Topics: Calcium; Child; Disease Progression; Diuretics; Female; Humans; Hydrochlorothiazide; Hypophosphatemi | 2001 |
11 other studies available for hydrochlorothiazide and Disease Exacerbation
| Article | Year |
|---|---|
Prostaglandin E2, Osmoregulation, and Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
Topics: Antidiuretic Hormone Receptor Antagonists; Dinoprostone; Disease Progression; Female; Glomerular Fil | 2023 |
Chlorothiazide-induced photoaggravation of psoriatic lesion during narrowband ultraviolet B treatment in a case of psoriasis vulgaris.
Topics: Aged; Disease Progression; Drug Combinations; Female; Ficusin; Humans; Hydrochlorothiazide; Hyperten | 2017 |
Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Desoxycorticosterone; Disease Models, Animal; Dise | 2008 |
Kidney injury molecule 1: in search of biomarkers of chronic tubulointerstitial damage and disease progression.
Topics: Animals; Antihypertensive Agents; Biomarkers; Chronic Disease; Disease Models, Animal; Disease Progr | 2009 |
Composite renal endpoints: was ACCOMPLISH accomplished?
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Calcium | 2010 |
Calcium-alkali syndrome-like symptoms manifested by daily alphacalcidol and thiazide.
Topics: Acute Kidney Injury; Aged; Blood Chemical Analysis; Combined Modality Therapy; Disease Progression; | 2010 |
Drug-induced chronic pancreatitis.
Topics: Acute Disease; Aged, 80 and over; Antihypertensive Agents; Disease Progression; Female; Humans; Hydr | 2012 |
Impaired fibrinolytic activity in type II diabetes: correlation with urinary albumin excretion and progression of renal disease.
Topics: Aged; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cohort Studies; Creat | 2006 |
Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Creatinine; Disease | 1999 |
Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Diabetic | 1999 |
Dent's disease: can we slow its progression?
Topics: Adolescent; Calcium; Disease Progression; Female; Humans; Hydrochlorothiazide; Hypophosphatemia; Kid | 2001 |